COMMUNIQUÉS West-GlobeNewswire

Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights
12/08/2024
- 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable [...]
Firefly Neuroscience Announces Closing of Merger Agreement and is Scheduled to Begin Trading on Nasdaq Under the Ticker Symbol ‘AIFF’ on August 13, 2024
12/08/2024
In connection with the consummation of the merger, the Company closed $3.5 million private placement offering FAIRFAX, Va. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “ [...]
Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX
12/08/2024
Latest innovation in Robotic Magnetic Navigation technology supports broad accessibility of robotics for minimally-invasive endovascular surgery GenesisX has obtained CE mark in Europe and has been submitted to the FDA [...]
Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
12/08/2024
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million [...]
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
12/08/2024
In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors Initiated SEACRAFT-2 [...]
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
12/08/2024
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy [...]
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
12/08/2024
BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025 BBI-825 STARMAP clinical trial [...]
Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
12/08/2024
WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a [...]
Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024
12/08/2024
SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. “We [...]
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21
12/08/2024
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and [...]
Eric Samples Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
12/08/2024
MINNEAPOLIS, MN, US, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical [...]
NeuroOne® to Report Third Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on August 14
12/08/2024
EDEN PRAIRIE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and [...]
Milestone Scientific Schedules Second Quarter 2024 Financial Results and Business Update Conference Call
12/08/2024
ROSELAND, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that [...]
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
12/08/2024
Press Release – No. 8 / 2024 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Copenhagen, Denmark, August 12, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: [...]
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
12/08/2024
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of [...]
Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
12/08/2024
SHANGHAI, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
NEXGEL to Report Second Quarter 2024 Financial Results on August 14th
12/08/2024
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over- [...]
60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
12/08/2024
University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. SJ733 will be combined with a single dose of tafenoquine in the study. The right of [...]
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
12/08/2024
ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab [...]

Pages